Diastolic Dysfunction And Hypertension

dc.creatorNadruz
dc.creatorWilson; Shah
dc.creatorAmil M.; Solomon
dc.creatorScott D.
dc.date2017
dc.datejan
dc.date2017-11-13T11:33:28Z
dc.date2017-11-13T11:33:28Z
dc.date.accessioned2018-03-29T05:47:56Z
dc.date.available2018-03-29T05:47:56Z
dc.identifierMedical Clinics Of North America. W B Saunders Co-elsevier Inc, v. 101, p. 7 - +, 2017.
dc.identifier0025-7125
dc.identifier1557-9859
dc.identifierWOS:000390970600004
dc.identifier10.1016/j.mcna.2016.08.013
dc.identifierhttp://www.medical.theclinics.com/article/S0025-7125(16)37332-1/abstract
dc.identifierhttp://repositorio.unicamp.br/jspui/handle/REPOSIP/326277
dc.identifier.urihttp://repositorioslatinoamericanos.uchile.cl/handle/2250/1363283
dc.descriptionLeft ventricular (LV) diastolic dysfunction (LVDD) is characterized by alterations in LV diastolic filling, and is a strong predictor of cardiovascular events and heart failure. Hypertension is the most important risk factor for LVDD in the community and promotes LVDD through several mechanisms, including hemodynamic overload and myocardial ischemia. Associated factors such as age, ethnicity, dietary sodium, obesity, diabetes mellitus, and chronic kidney disease also contribute to LVDD in hypertensive individuals. Blood pressure lowering using antihypertensive medications can improve LVDD; however, it remains unclear whether this improvement in LV diastolic function can improve cardiovascular outcomes.
dc.description101
dc.description1
dc.description7
dc.description+
dc.languageEnglish
dc.publisherW B Saunders Co-Elsevier Inc
dc.publisherPhiladelphia
dc.relationMedical Clinics of North America
dc.rightsfechado
dc.sourceWOS
dc.subjectHypertension
dc.subjectDiastolic Dysfunction
dc.subjectHeart Failure
dc.subjectLeft Ventricular Hypertrophy
dc.titleDiastolic Dysfunction And Hypertension
dc.typeArtículos de revistas


Este ítem pertenece a la siguiente institución